These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 9030661

  • 21. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 22. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L.
    Vaccine; 2007 May 22; 25(21):4159-69. PubMed ID: 17395340
    [Abstract] [Full Text] [Related]

  • 23. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S, Ghaemimanesh F, Zahedifard F.
    Vaccine; 2006 Apr 12; 24(16):3290-7. PubMed ID: 16481076
    [Abstract] [Full Text] [Related]

  • 24. Dichotomy of protective cellular immune responses to human visceral leishmaniasis.
    Khalil EA, Ayed NB, Musa AM, Ibrahim ME, Mukhtar MM, Zijlstra EE, Elhassan IM, Smith PG, Kieny PM, Ghalib HW, Zicker F, Modabber F, Elhassan AM.
    Clin Exp Immunol; 2005 May 12; 140(2):349-53. PubMed ID: 15807861
    [Abstract] [Full Text] [Related]

  • 25. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
    Garg R, Gupta SK, Tripathi P, Hajela K, Sundar S, Naik S, Dube A.
    Vaccine; 2006 Apr 05; 24(15):2900-9. PubMed ID: 16448729
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.
    Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, Belkaid Y, Sacks DL.
    Infect Immun; 2005 Oct 05; 73(10):6620-8. PubMed ID: 16177338
    [Abstract] [Full Text] [Related]

  • 28. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis.
    Tafaghodi M, Eskandari M, Khamesipour A, Jaafari MR.
    Exp Parasitol; 2011 Oct 05; 129(2):107-14. PubMed ID: 21767536
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E, Casas CP, Borja-Cabrera GP, Santos FN, Nico D, Souza LO, Tinoco LW, da Silva BP, Palatnik M, Parente JP, Palatnik-de-Sousa CB.
    Vaccine; 2006 May 01; 24(18):3909-20. PubMed ID: 16556475
    [Abstract] [Full Text] [Related]

  • 31. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P, Pandya J, Mehta J, Sukumaran B, Madhubala R.
    FEMS Immunol Med Microbiol; 2004 Oct 01; 42(2):241-8. PubMed ID: 15364110
    [Abstract] [Full Text] [Related]

  • 32. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines.
    Arora SK, Pal NS, Mujtaba S.
    Exp Parasitol; 2005 Mar 01; 109(3):163-70. PubMed ID: 15713447
    [Abstract] [Full Text] [Related]

  • 33. Leishmania major infections in Phlebotomus duboscqi fed on murine models immunized with L. major subcellular antigens and sandfly gut antigens.
    Mbati PA, Anjili CO, Odongo S, Ogaja P, Tonui W.
    Onderstepoort J Vet Res; 2000 Mar 01; 67(1):57-63. PubMed ID: 10843323
    [Abstract] [Full Text] [Related]

  • 34. Leishmania-induced cellular recruitment during the early inflammatory response: modulation of proinflammatory mediators.
    Matte C, Olivier M.
    J Infect Dis; 2002 Mar 01; 185(5):673-81. PubMed ID: 11865425
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, Rodrigues RC, Charest H, Matlashewski G, Gazzinelli RT, Fernandes AP.
    Infect Immun; 2003 Jul 01; 71(7):3988-94. PubMed ID: 12819086
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK, Naskar K, De T.
    Eur J Immunol; 2009 Aug 01; 39(8):2146-60. PubMed ID: 19593771
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.